Literature DB >> 23625360

Do acetylcholine receptor and striated muscle antibodies predict the presence of thymoma in patients with myasthenia gravis?

Emily Choi Decroos1, Lisa D Hobson-Webb, Vern C Juel, Janice M Massey, Donald B Sanders.   

Abstract

INTRODUCTION: Acetylcholine receptor (AChR) and striated muscle antibodies (StrAbs) are found frequently in myasthenia gravis (MG) patients with thymoma. In this study we aimed to determine the positive predictive value (PPV) and negative predictive value (NPV) of these antibodies for thymoma in patients with MG.
METHODS: Antibody findings, thymic histology, and onset age were reviewed for 1141 patients with MG. PPV and NPV of these antibodies for thymoma were determined.
RESULTS: The PPV of AChR binding antibodies plus StrAbs was highest (50.0%) with onset before the age of 40 years. The PPV of all antibodies was low (<9%) after age 40. Higher StrAb levels did not increase the PPV. The NPV of AChR binding antibodies was high (99.7%) for all ages.
CONCLUSIONS: Patients without AChR binding antibody are not likely to have a thymoma. StrAbs and AChR binding antibodies are not diagnostic for thymoma, but in early-onset MG their presence should raise the clinical suspicion for thymoma.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  acetylcholine receptor antibody; myasthenia gravis predictive value; striated muscle antibody; thymoma

Mesh:

Substances:

Year:  2013        PMID: 23625360     DOI: 10.1002/mus.23882

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  6 in total

Review 1.  Myasthenia Gravis: Autoantibody Specificities and Their Role in MG Management.

Authors:  Konstantinos Lazaridis; Socrates J Tzartos
Journal:  Front Neurol       Date:  2020-11-30       Impact factor: 4.003

2.  A Stable Cell Line Expressing Clustered AChR: A Novel Cell-Based Assay for Anti-AChR Antibody Detection in Myasthenia Gravis.

Authors:  Yu Cai; Lu Han; Desheng Zhu; Jing Peng; Jianping Li; Jie Ding; Jiaying Luo; Ronghua Hong; Kan Wang; Wenbin Wan; Chong Xie; Xiajun Zhou; Ying Zhang; Yong Hao; Yangtai Guan
Journal:  Front Immunol       Date:  2021-07-08       Impact factor: 7.561

3.  Pure White Cell Aplasia and Necrotizing Myositis.

Authors:  Peter Geon Kim; Joome Suh; Max W Adelman; Kwadwo Oduro; Erik Williams; Andrew M Brunner; David J Kuter
Journal:  Case Rep Hematol       Date:  2016-03-17

Review 4.  Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics.

Authors:  Konstantinos Lazaridis; Socrates J Tzartos
Journal:  Front Immunol       Date:  2020-02-14       Impact factor: 7.561

5.  Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature.

Authors:  Houssein Safa; Daniel H Johnson; Van Anh Trinh; Theresa E Rodgers; Heather Lin; Maria E Suarez-Almazor; Faisal Fa'ak; Chantal Saberian; Cassian Yee; Michael A Davies; Sudhakar Tummala; Karin Woodman; Noha Abdel-Wahab; Adi Diab
Journal:  J Immunother Cancer       Date:  2019-11-21       Impact factor: 13.751

6.  Myasthenia Gravis: From the Viewpoint of Pathogenicity Focusing on Acetylcholine Receptor Clustering, Trans-Synaptic Homeostasis and Synaptic Stability.

Authors:  Masaharu Takamori
Journal:  Front Mol Neurosci       Date:  2020-05-28       Impact factor: 5.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.